Apogee Therapeutics to Participate in Upcoming November Investor Conferences
Apogee Therapeutics (APGE), a clinical-stage biotech company focused on inflammatory and immunology treatments, announces its participation in three major investor conferences this November. The company will present at the Guggenheim Inaugural Healthcare Innovation Conference on November 12 at 3:00 p.m. ET, the Stifel 2024 Healthcare Conference on November 18 at 10:20 a.m. ET, and the Jefferies London Healthcare Conference on November 20 at 10:30 a.m. ET. Live and archived webcasts will be accessible through Apogee's website investor section.
Apogee Therapeutics (APGE), un'azienda biotecnologica in fase clinica focalizzata sui trattamenti per le infiammazioni e l'immunologia, annuncia la sua partecipazione a tre importanti conferenze per investitori questo novembre. L'azienda presenterà al Guggenheim Inaugural Healthcare Innovation Conference il 12 novembre alle 15:00 ET, alla Stifel 2024 Healthcare Conference il 18 novembre alle 10:20 ET, e alla Jefferies London Healthcare Conference il 20 novembre alle 10:30 ET. Saranno disponibili webcast in diretta e registrati nella sezione investitori del sito web di Apogee.
Apogee Therapeutics (APGE), una empresa biotecnológica en etapa clínica centrada en tratamientos para inflamaciones e inmunología, anuncia su participación en tres importantes conferencias de inversionistas este noviembre. La compañía presentará en la Guggenheim Inaugural Healthcare Innovation Conference el 12 de noviembre a las 3:00 p.m. ET, en la Stifel 2024 Healthcare Conference el 18 de noviembre a las 10:20 a.m. ET, y en la Jefferies London Healthcare Conference el 20 de noviembre a las 10:30 a.m. ET. Se podrán acceder a webcasts en vivo y grabados a través de la sección de inversionistas del sitio web de Apogee.
Apogee Therapeutics (APGE)는 염증 및 면역학 치료에 중점을 둔 임상 단계의 생명공학 회사로, 이번 11월에 3개의 주요 투자자 회의에 참여한다고 발표했습니다. 회사는 11월 12일 오후 3시(ET)에 개최되는 구겐하임 초대 의료 혁신 회의, 11월 18일 오전 10시 20분(ET)에 개최되는 스티펠 2024 의료 회의, 그리고 11월 20일 오전 10시 30분(ET)에 개최되는 제프리즈 런던 의료 회의에서 발표를 진행할 예정입니다. Apogee의 웹사이트의 투자자 섹션을 통해 실시간 및 기록된 웹캐스트에 접근할 수 있습니다.
Apogee Therapeutics (APGE), une entreprise biopharmaceutique en phase clinique axée sur les traitements des inflammations et de l'immunologie, annonce sa participation à trois grandes conférences pour investisseurs ce mois de novembre. L'entreprise présentera à la Guggenheim Inaugural Healthcare Innovation Conference le 12 novembre à 15h00 ET, à la Stifel 2024 Healthcare Conference le 18 novembre à 10h20 ET, et à la Jefferies London Healthcare Conference le 20 novembre à 10h30 ET. Des webdiffusions en direct et enregistrées seront accessibles via la section investisseurs du site web d'Apogee.
Apogee Therapeutics (APGE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Entzündungs- und Immunbehandlungen konzentriert, gibt seine Teilnahme an drei wichtigen Investorenkonferenzen im November bekannt. Das Unternehmen wird am 12. November um 15:00 Uhr ET auf der Guggenheim Inaugural Healthcare Innovation Conference, am 18. November um 10:20 Uhr ET auf der Stifel 2024 Healthcare Conference und am 20. November um 10:30 Uhr ET auf der Jefferies London Healthcare Conference präsentieren. Live und archivierte Webcasts werden über den Investorenbereich der Website von Apogee zugänglich sein.
- None.
- None.
SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management will participate at the following investor conferences.
Guggenheim Inaugural Healthcare Innovation Conference
Date: Tuesday, November 12, 2024
Time: 3:00 p.m. ET
Stifel 2024 Healthcare Conference
Date: Monday, November 18, 2024
Time: 10:20 a.m. ET
Jefferies London Healthcare Conference
Date: Wednesday, November 20, 2024
Time: 3:30 a.m. GMT / 10:30 a.m. ET
A live and archived webcast of the fireside chats and presentations will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
What investor conferences is Apogee Therapeutics (APGE) attending in November 2024?
When is Apogee Therapeutics (APGE) presenting at the Guggenheim Healthcare Conference 2024?
How can investors access Apogee Therapeutics (APGE) conference presentations?
What therapeutic areas does Apogee Therapeutics (APGE) focus on?
